Trial
NCT01251965
Phase l/II Study of Ruxolitinib for Acute Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
Incyte Corporation
Condition
Leukemia
Intervention
Ruxolitinib
Why stopped
Study was stopped by the principal investigator due to nonsatisfactory clinical benefit even in patients treated at the highest dose (200 mg ).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-08